These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 20922701

  • 1. [Minimizing the risk of cancer in transplant patients].
    Campistol JM.
    G Ital Nefrol; 2010; 27 Suppl 50():S81-5. PubMed ID: 20922701
    [Abstract] [Full Text] [Related]

  • 2. Minimizing the risk of posttransplant malignancy.
    Campistol JM.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S40-3. PubMed ID: 19100906
    [Abstract] [Full Text] [Related]

  • 3. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 4. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L, Kamar N.
    J Nephrol; 2010 Nov; 23(2):133-42. PubMed ID: 20155724
    [Abstract] [Full Text] [Related]

  • 5. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H.
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [Abstract] [Full Text] [Related]

  • 6. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 7. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T, Kreis H, Friend P.
    Clin Transplant; 2004 Aug 27; 18(4):446-9. PubMed ID: 15233824
    [Abstract] [Full Text] [Related]

  • 8. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR.
    Nephrol Dial Transplant; 2007 May 27; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [Abstract] [Full Text] [Related]

  • 9. [Pro and anti-neoplastic effects of immunosuppressive drug in renal transplantation].
    Infante B, Stallone G, Schena A, Maiorano A, Gesualdo L, Schena FP, Grandaliano G.
    G Ital Nefrol; 2006 May 27; 23(4):389-95. PubMed ID: 17063439
    [Abstract] [Full Text] [Related]

  • 10. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B.
    Transpl Int; 2004 Jul 27; 17(6):279-85. PubMed ID: 15221123
    [Abstract] [Full Text] [Related]

  • 11. Conversion to sirolimus in posttransplant renal neoplasms.
    Lopez V, Gutierrez C, Cabello M, Burgos D, Sola E, Gonzalez-Molina M.
    Transplant Proc; 2007 Sep 27; 39(7):2264-6. PubMed ID: 17889158
    [Abstract] [Full Text] [Related]

  • 12. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 13. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 27; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 14. Conversion to a proliferation signal inhibitor in a patient with coronary artery disease--a case report.
    Sparacino V, Calabrese S.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii34-7. PubMed ID: 16815856
    [Abstract] [Full Text] [Related]

  • 15. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M.
    Clin Transplant; 2007 Jul 27; 21(3):305-8. PubMed ID: 17488377
    [Abstract] [Full Text] [Related]

  • 16. [Skin cancer in renal transplant recipients].
    Mangino M, Schena FP.
    G Ital Nefrol; 2010 Jul 27; 27 Suppl 50():S75-80. PubMed ID: 20922700
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec 27; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 18. Intrarenal vascular resistance parameters in kidney transplant patients receiving calcineurin inhibitor-based or sirolimus-based regimens.
    Lee PC, Lee CY, Hu RH, Lo C, Tsai MK, Lee PH.
    Nephrol Dial Transplant; 2010 May 27; 25(5):1675-80. PubMed ID: 20042398
    [Abstract] [Full Text] [Related]

  • 19. The role and value of sirolimus administration in kidney and liver transplantation.
    Mehrabi A, Fonouni H, Kashfi A, Schmied BM, Morath Ch, Sadeghi M, Schemmer P, Encke J, Sauer P, Zeier M, Weitz J, Büchler MW, Schmidt J.
    Clin Transplant; 2006 May 27; 20 Suppl 17():30-43. PubMed ID: 17100699
    [Abstract] [Full Text] [Related]

  • 20. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
    Steigerwalt SP, Brar N, Dhungel A, Butcher D, Steigerwalt S, El-Ghouroury M, Provenzano R.
    Transplant Proc; 2009 Dec 27; 41(10):4184-7. PubMed ID: 20005365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.